Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 20/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 11/20 | 0.53 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5201166 | 0.81 | TGFBR1 (0.48) | TGFBR1MAPK14 | |
| SCHEMBL2047169 | 0.79 | TGFBR1 (0.56) | TGFBR1MAPK14MTOR | |
| SCHEMBL411346 | 0.79 | TGFBR1 (0.51) | TGFBR1MAPK14MTOR | |
| SCHEMBL7100715 | 0.77 | METAP2 (0.40) | TGFBR1MAPK14 | |
| SCHEMBL413574 | 0.76 | PIK3CD (0.45) | TGFBR1MAPK14MTOR | |
| SCHEMBL6757519 | 0.76 | TGFBR1 (0.74) | TGFBR1MAPK14MTOR | |
| SCHEMBL6761614 | 0.76 | TGFBR1 (0.61) | TGFBR1MAPK14MTOR | |
| SCHEMBL6316044 | 0.75 | TGFBR1 (0.43) | TGFBR1MAPK14 | |
| SCHEMBL6323134 | 0.75 | IDO1 (0.42) | TGFBR1MAPK14 | |
| SCHEMBL412990 | 0.75 | TGFBR1 (0.60) | TGFBR1MAPK14MTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040152738-A1 | Pyridyl-substituted triazoles as tgf inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-08-05 | — | — | US | disclosed |
| EP-1335916-A1 | PYRIDYL-SUBSTITUTED TRIAZOLES AS TGF INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-08-20 | — | — | EP | disclosed |
| WO-2002040476-A1 | PYRIDYL-SUBSTITUTED TRIAZOLES AS TGF INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152738-A1 | Pyridyl-substituted triazoles as tgf inhibitors | TGFBR1, TGFBR2, SMAD3 | TGFBR1 1/4885MAPK14 2320/4885MTOR 3078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.